沙库巴曲缬沙坦对射血分数降低性心衰患者心功能及炎症因子的影响

Effects of Salkubatrol Valsartan on Cardiac Function and Inflammatory Factors in Patients with Heart Failure Caused by Decreased Ejection Fraction

【目的】探讨沙库巴曲缬沙坦(S/V)对射血分数降低性心衰(HFrEF)患者心功能及炎症因子的影响。【方法】选择本院收治的104例HFrEF患者,根据随机数表法将其分为观察组与对照组,每组52例。对照组给予抗心衰常规治疗,观察组在对照组基础上给予S/V治疗。比较治疗期间两组不良反应、治疗3个月后两组临床疗效及治疗前后两组心功能参数[左心房内径(LA)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]、血流介导血管舒张(FMD)功能、炎症因子[白细胞介素-6(IL-6)、白细胞介素-33(IL-33)、肿瘤坏死因子-α(TNF-α)、细胞间黏附因子-1(ICAM-1)]水平,并随访半年记录两组再住院率。【结果】观察组总有效率为96.15%,高于对照组的75.00%,差异有统计学意义(P<0.05)。治疗后,两组患者LVEF、FMD均高于治疗前,LVEDD、LA均低于治疗前,且观察组与对照组比较差异均有统计学意义(P<0.05);两组患者血清IL-6、IL-33、ICAM-1、TNF-α水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组治疗期间不良反应总发生率及随访半年内再住院率比较,差异无统计学意义(P>0.05)。【结论】在常规治疗基础上加用S/V治疗HFrEF可显著提升临床疗效,改善患者心功能,并可减少炎症反应,安全性较好,值得临床推广。

【Objective】To investigate the effect of salkubatrol valsartan(S/V)on heart failure with reduced ejection fraction.【Methods】A total of 104 patients with HFREF was randomly divided into observation group and control group,with 52 cases in each group.The control group was given routine anti heart failure treatment,and the observation group was given S/V treatment on the basis of the control group.The adverse reactions,clinical efficacy after 3 months of treatment and before and after treatment and the levels of cardiac function parameters in the two groups were compared between the two groups included left atrial diameter(LA),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),blood flow mediated vasodilation(FMD),inflammatory factors[interleukin-6(IL-6),interleukin-33(IL-33),and tumor necrosis factor-α(TNF-α)and intercellular adhesion factor-1(ICAM-1)],and the rehospitalization rates of the two groups were recorded.【Results】The total effective rate in the observation group was 96.15%,higher than 75.00%in the control group,The difference was statistically significant(P<0.05).After treatment,LVEF and FMD in the two groups were higher than those before treatment,LVEDD and LA were lower than those before treatment,and the levels of serum IL-6,IL-33 and ICAM-1 in the observation group were lower than those before treatment(P<0.05).There was no significant difference between the two groups in the total incidence of adverse reactions during treatment and rehospitalization rate within half a year of follow-up(P>0.05).【Conclusion】The addition of S/V to HFREF on the basis of routine treatment can significantly improve the clinical efficacy,improve the cardiac function of patients,and reduce inflammatory reaction.It has good safety and is worthy of clinical promotion.